ZA966934B - Prostaglandin derivatives. - Google Patents

Prostaglandin derivatives.

Info

Publication number
ZA966934B
ZA966934B ZA9606934A ZA966934A ZA966934B ZA 966934 B ZA966934 B ZA 966934B ZA 9606934 A ZA9606934 A ZA 9606934A ZA 966934 A ZA966934 A ZA 966934A ZA 966934 B ZA966934 B ZA 966934B
Authority
ZA
South Africa
Prior art keywords
ch2ch2
formula
blood flow
prostaglandin derivatives
prostaglandin
Prior art date
Application number
ZA9606934A
Other languages
English (en)
Inventor
Akio Nishiura
Ryoji Matsumoto
Takuya Seko
Shin-Ichi Hamano
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of ZA966934B publication Critical patent/ZA966934B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ZA9606934A 1995-08-16 1996-08-15 Prostaglandin derivatives. ZA966934B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP23076395 1995-08-16

Publications (1)

Publication Number Publication Date
ZA966934B true ZA966934B (en) 1997-02-19

Family

ID=16912888

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9606934A ZA966934B (en) 1995-08-16 1996-08-15 Prostaglandin derivatives.

Country Status (16)

Country Link
US (1) US5690957A (de)
EP (1) EP0758645B1 (de)
KR (1) KR100225689B1 (de)
CN (1) CN1058706C (de)
AT (1) ATE185559T1 (de)
AU (1) AU708905B2 (de)
CA (1) CA2183486C (de)
DE (1) DE69604631T2 (de)
DK (1) DK0758645T3 (de)
ES (1) ES2140032T3 (de)
GR (1) GR3032274T3 (de)
HU (1) HUP9602262A3 (de)
MX (1) MX9603452A (de)
NO (1) NO309086B1 (de)
TW (1) TW367324B (de)
ZA (1) ZA966934B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2326354B1 (es) * 2005-04-13 2010-07-08 Elan Pharma International Limited Composiciones de liberacion controlada y nanoparticuladas que comprenden derivados de prostaglandina.
CN1813679A (zh) * 2005-11-30 2006-08-09 上海医药(集团)有限公司 一种紫杉烷脂质体冻干组合物及其制备方法
WO2007074604A1 (ja) * 2005-12-26 2007-07-05 Ltt Bio-Pharma Co., Ltd. 水溶性非ペプチド性低分子薬物含有ナノ粒子
CN103804338A (zh) * 2006-02-07 2014-05-21 株式会社·R-技术上野 用于制备前列腺素衍生物的方法
KR101513318B1 (ko) * 2007-05-14 2015-04-17 가부시키가이샤 엘티티 바이오파마 서방성의 음하전기를 갖는 저분자 약물 함유 나노 입자
ITCA20080017A1 (it) * 2008-07-31 2010-02-01 Giuseppe Brotzu Farmaco a base di liposomi di fosfatidilcolina trasportanti una prostaglandina e1 legata alla alfa-ciclodestrina per il trattamento delle microngiopatie diabetiche e altre patologie vascolari.
WO2010058669A1 (ja) * 2008-11-18 2010-05-27 株式会社Lttバイオファーマ 新規プロスタグランジンe1誘導体及びそれを封入するナノ粒子
US8569279B2 (en) 2009-05-27 2013-10-29 Sucampo Ag Method for modulating claudin mediated functions
CN102448463A (zh) * 2009-05-27 2012-05-09 苏坎波公司 用于调节紧密连接蛋白介导的功能和治疗皮肤病的包含前列腺素衍生物的药物组合物
CN102028696B (zh) * 2009-09-24 2013-02-13 上海天伟生物制药有限公司 一种前列腺素类化合物的用途
CN101912363A (zh) * 2010-07-29 2010-12-15 蔡海德 溶解超滤-喷雾干燥-分子分散包衣-水化制粒-冷冻干燥生产脂质体组合药物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4054736A (en) * 1970-06-10 1977-10-18 Ono Pharmaceutical Co., Ltd. Clathrate compounds of prostaglandins or their analogues with cyclodextrin
JPS59206349A (ja) * 1983-05-10 1984-11-22 Green Cross Corp:The プロスタグランジンe↓1誘導体

Also Published As

Publication number Publication date
DK0758645T3 (da) 1999-12-27
HUP9602262A3 (en) 1997-08-28
EP0758645B1 (de) 1999-10-13
KR970010742A (ko) 1997-03-27
CN1151398A (zh) 1997-06-11
CA2183486C (en) 2002-03-26
DE69604631T2 (de) 2000-02-17
NO963408D0 (no) 1996-08-15
KR100225689B1 (ko) 1999-10-15
AU708905B2 (en) 1999-08-12
MX9603452A (es) 1997-03-29
ATE185559T1 (de) 1999-10-15
TW367324B (en) 1999-08-21
US5690957A (en) 1997-11-25
NO309086B1 (no) 2000-12-11
CN1058706C (zh) 2000-11-22
GR3032274T3 (en) 2000-04-27
EP0758645A1 (de) 1997-02-19
DE69604631D1 (de) 1999-11-18
HUP9602262A2 (en) 1997-05-28
HU9602262D0 (en) 1996-10-28
ES2140032T3 (es) 2000-02-16
NO963408L (no) 1997-02-17
AU6210596A (en) 1997-02-20
CA2183486A1 (en) 1997-02-17

Similar Documents

Publication Publication Date Title
CA2259621A1 (en) Isocoumarin derivatives and their use in medicines
FR2416012A1 (fr) Derives de l'imidazole et medicament contenant ces substances
IL112572A0 (en) Dexanabinol derivatives and their use as nmda blocking pharmaceutical compositions
ATE157346T1 (de) Hexahydronapththalinesterderivate, ihre herstellung und ihre therapeutischen verwendungen
GR3032274T3 (en) Prostaglandin derivatives
KR890003382A (ko) 항 비루스성 화합물
TNSN87012A1 (fr) Nouveaux derives de dihydrobenzofuranne - et de chromane - carboxamides, leurs procedes de preparation et leur utilisation comme neuroleptiques
AU1792700A (en) Compositions for the treatment of skin diseases
MA23639A1 (fr) Derives pyrrocarbazole, leur preparation, les compositions pharmaceutiques les contenant, leur utilisation dans le traitement des tumeurs malignes.
AU3453493A (en) Pharmaceutical preparation based on rhamnolipid against dermatological diseases, e.g. papilloma virus infections
DE69413118D1 (de) Benzolsulfonamid-Derivate zur Behandlung der Blaseninstabilität
DE69312567D1 (de) 2-Formylpyridin-Thiosemicarbazonderivate, ihre Herstellung und ihre Verwendung als Antitumor Mittel
MA26725A1 (fr) Derives de resorcinol, compositions pharmaceutiques les contenant et procede pour leur preparation
BR9503572A (pt) Composto composiçao farmaceutica e método de tratamento ou prevençao de uma doença
GR3033195T3 (en) Prostaglandin derivatives
NZ246598A (en) Trazodone derivatives; compounds and preparation, pharmaceutical compositions; intermediate compounds
ITMI922742A1 (it) Composti ad attivita' terapeutica utili per il trattamento di malattie connesse ad una carenza di glutatione, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.
ZA939153B (en) Use of idazoxan and its derivatives for the preparation of a medicinal product intended for the treatment of parkinson's disease and its development
AU1645897A (en) Benzopyran derivative and use of said benzopyran derivative for treating heart disease
MA26626A1 (fr) Derives de 2"-desoxy-hygromycine a nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
ES2134441T3 (es) Benzonitrilos terapeuticos.
HU194734B (en) Process for production of medical and applicable for human consumption products suitable for treatment and/or prevention of diseases caused by free-radical reactions
DE69330269D1 (de) Benzopyran-derivate, deren herstellung sowie diese als aktive bestandteile enthaltende arzneimittel
FR2414333A2 (fr) Composition pharmaceutique contenant comme ingredient actif la d-2-bromo 6-methyl-8b-(morpholinocarbonyoxymethyl)-ergoline, utile notamment pour le traitement de l'asthme
EP0178176A3 (en) Tetrahydro-1,2,4-oxadiazine-5-thione derivatives